|
Gene: RPL10 |
Gene summary for RPL10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RPL10 | Gene ID | 6134 |
Gene name | ribosomal protein L10 | |
Gene Alias | AUTSX5 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0000027 | UniProtAcc | P27635 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6134 | RPL10 | GSM4909281 | Human | Breast | IDC | 1.93e-70 | -3.66e-01 | 0.21 |
6134 | RPL10 | GSM4909293 | Human | Breast | IDC | 7.06e-59 | -2.72e-01 | 0.1581 |
6134 | RPL10 | GSM4909296 | Human | Breast | IDC | 2.34e-18 | 1.50e-01 | 0.1524 |
6134 | RPL10 | GSM4909297 | Human | Breast | IDC | 1.58e-05 | -9.40e-02 | 0.1517 |
6134 | RPL10 | GSM4909298 | Human | Breast | IDC | 1.63e-20 | -1.38e-01 | 0.1551 |
6134 | RPL10 | GSM4909300 | Human | Breast | IDC | 2.35e-02 | 6.13e-02 | 0.0334 |
6134 | RPL10 | GSM4909302 | Human | Breast | IDC | 8.24e-08 | 9.93e-02 | 0.1545 |
6134 | RPL10 | GSM4909305 | Human | Breast | IDC | 5.30e-06 | 9.46e-02 | 0.0436 |
6134 | RPL10 | GSM4909307 | Human | Breast | IDC | 8.57e-11 | 1.11e-01 | 0.1569 |
6134 | RPL10 | GSM4909308 | Human | Breast | IDC | 1.43e-05 | 8.29e-02 | 0.158 |
6134 | RPL10 | GSM4909309 | Human | Breast | IDC | 4.23e-04 | 4.70e-02 | 0.0483 |
6134 | RPL10 | GSM4909312 | Human | Breast | IDC | 1.75e-02 | 8.33e-02 | 0.1552 |
6134 | RPL10 | GSM4909313 | Human | Breast | IDC | 4.17e-02 | 6.84e-02 | 0.0391 |
6134 | RPL10 | GSM4909317 | Human | Breast | IDC | 1.57e-13 | -2.06e-01 | 0.1355 |
6134 | RPL10 | GSM4909318 | Human | Breast | IDC | 2.12e-04 | -2.84e-01 | 0.2031 |
6134 | RPL10 | GSM4909319 | Human | Breast | IDC | 1.36e-10 | 1.08e-01 | 0.1563 |
6134 | RPL10 | GSM4909320 | Human | Breast | IDC | 1.95e-03 | 9.30e-02 | 0.1575 |
6134 | RPL10 | brca2 | Human | Breast | Precancer | 3.38e-14 | -1.34e-01 | -0.024 |
6134 | RPL10 | M2 | Human | Breast | IDC | 2.23e-05 | -2.95e-01 | 0.21 |
6134 | RPL10 | M5 | Human | Breast | IDC | 4.24e-03 | -2.54e-01 | 0.1598 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
GO:00718269 | Breast | Precancer | ribonucleoprotein complex subunit organization | 48/1080 | 227/18723 | 2.68e-15 | 8.45e-13 | 48 |
GO:00226189 | Breast | Precancer | ribonucleoprotein complex assembly | 47/1080 | 220/18723 | 3.47e-15 | 1.03e-12 | 47 |
GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00422559 | Breast | Precancer | ribosome assembly | 21/1080 | 61/18723 | 1.06e-11 | 1.53e-09 | 21 |
GO:00422739 | Breast | Precancer | ribosomal large subunit biogenesis | 22/1080 | 72/18723 | 5.03e-11 | 5.61e-09 | 22 |
GO:00000279 | Breast | Precancer | ribosomal large subunit assembly | 9/1080 | 27/18723 | 1.24e-05 | 3.19e-04 | 9 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
GO:007182614 | Breast | IDC | ribonucleoprotein complex subunit organization | 52/1434 | 227/18723 | 5.18e-13 | 1.21e-10 | 52 |
GO:002261814 | Breast | IDC | ribonucleoprotein complex assembly | 51/1434 | 220/18723 | 5.32e-13 | 1.21e-10 | 51 |
GO:000641714 | Breast | IDC | regulation of translation | 74/1434 | 468/18723 | 1.67e-09 | 1.53e-07 | 74 |
GO:004225514 | Breast | IDC | ribosome assembly | 21/1434 | 61/18723 | 1.98e-09 | 1.76e-07 | 21 |
GO:004227314 | Breast | IDC | ribosomal large subunit biogenesis | 22/1434 | 72/18723 | 1.04e-08 | 7.67e-07 | 22 |
GO:004225414 | Breast | IDC | ribosome biogenesis | 52/1434 | 299/18723 | 1.90e-08 | 1.32e-06 | 52 |
GO:000002714 | Breast | IDC | ribosomal large subunit assembly | 9/1434 | 27/18723 | 1.17e-04 | 2.17e-03 | 9 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPL10 | SNV | Missense_Mutation | c.440A>G | p.His147Arg | p.H147R | P27635 | protein_coding | tolerated(0.13) | benign(0.009) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
RPL10 | SNV | Missense_Mutation | c.291C>G | p.Ile97Met | p.I97M | P27635 | protein_coding | deleterious(0.02) | possibly_damaging(0.819) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD | |
RPL10 | SNV | Missense_Mutation | novel | c.208N>C | p.Ile70Leu | p.I70L | P27635 | protein_coding | deleterious(0) | benign(0.266) | TCGA-AC-A5EH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RPL10 | SNV | Missense_Mutation | c.94N>T | p.Arg32Cys | p.R32C | P27635 | protein_coding | tolerated(0.11) | benign(0.006) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
RPL10 | SNV | Missense_Mutation | c.470N>C | p.Phe157Ser | p.F157S | P27635 | protein_coding | deleterious(0) | benign(0.065) | TCGA-E9-A1N8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
RPL10 | SNV | Missense_Mutation | c.559N>A | p.Glu187Lys | p.E187K | P27635 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-C5-A1MP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
RPL10 | SNV | Missense_Mutation | novel | c.130N>C | p.Asp44His | p.D44H | P27635 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-VS-A8QC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | PD |
RPL10 | SNV | Missense_Mutation | c.16G>A | p.Ala6Thr | p.A6T | P27635 | protein_coding | deleterious(0.03) | benign(0.078) | TCGA-CM-5349-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RPL10 | SNV | Missense_Mutation | c.296T>C | p.Ile99Thr | p.I99T | P27635 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPL10 | SNV | Missense_Mutation | novel | c.229G>A | p.Val77Ile | p.V77I | P27635 | protein_coding | tolerated(0.17) | benign(0.105) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6134 | RPL10 | CLINICALLY ACTIONABLE | TRANSFORMING GROWTH FACTOR | 15345329 |
Page: 1 |